Evaluation of wound healing and anti-inflammatory activity of hydro-alcoholic extract and solvent fractions of the leaves of Clerodendrum myricoides (Lamiaceae) in mice.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Plant Extracts*/pharmacology ; Plant Extracts*/chemistry ; Wound Healing*/drug effects ; Plant Leaves*/chemistry ; Clerodendrum*/chemistry ; Anti-Inflammatory Agents*/pharmacology ; Anti-Inflammatory Agents*/chemistry; Animals ; Mice ; Male ; Solvents/chemistry ; Edema/drug therapy ; Female ; Carrageenan

Background: Wounds significantly affect people's quality of life and the clinical and financial burden of healthcare systems around the world. Many of the current drugs used to treat wounds have problems such as; allergies and drug resistance. Hence, the exploration of new therapeutic agents from natural origin may avert this problem. Clerodendrum myricoides have long been used to treat wounds in Ethiopia. Despite this, nothing has so far been reported about the wound healing and anti-inflammatory activity of C. myricoides. This study aimed to evaluate the wound healing and anti-inflammatory activity of 80% methanol extract and solvent fractions of C. myricoides leaves in mice.
Methods: Leaves of C. myricoides were extracted using the maceration technique. The extract was formulated as 5% and 10% w/w ointments. The wound healing activity of the extract was evaluated using excision, incision, and burn wound models whereas the healing activities of solvent fractions were evaluated using the excision wound model. A carrageenan-induced paw edema model was used for the anti-inflammatory test.
Results: In the dermal toxicity test, 2000 mg/kg of 10% extract was found to be safe. In excision and burn wound models, treatment with 10% and 5% extract showed a significant (p<0.001) wound contraction. Solvent fractions of the extract significantly reduced wound contraction. A significant reduction in periods of epithelialization and favorable histopathology changes were shown by extract ointments. In incision wounds, 10% (p<0.001) and 5% (p<0.01) extracts significantly increase skin-breaking strength. After one hour of treatment, 400 mg/kg (p<0.001) and 200 mg/kg (p<0.05) showed significant reduction in paw edema.
Conclusion: Results of this study indicate that 80% methanol extract and the solvent fraction of the leaves of C. myricoides possess wound-healing and anti-inflammatory activity and support traditional claims.
Competing Interests: the authors have declared that no competing interests exist.
(Copyright: © 2024 Beyna et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Drug Des Devel Ther. 2016 May 24;10:1715-30. (PMID: 27307703)
J Ethnobiol Ethnomed. 2015 Mar 15;11:22. (PMID: 25889411)
Adv Wound Care (New Rochelle). 2021 May;10(5):281-292. (PMID: 33733885)
J Wound Care. 2020 May 1;29(Sup5b):S4-S10. (PMID: 32427027)
Evid Based Complement Alternat Med. 2011;2011:438056. (PMID: 21716711)
J Ethnopharmacol. 2012 Sep 28;143(2):469-74. (PMID: 22771316)
J Ethnopharmacol. 2011 Jun 1;135(3):792-6. (PMID: 21527332)
Phytother Res. 2010 Dec;24(12):1807-12. (PMID: 20564509)
Biomed Res Int. 2013;2013:972028. (PMID: 23984424)
Adv Wound Care (New Rochelle). 2015 Sep 1;4(9):560-582. (PMID: 26339534)
Environ Toxicol Pharmacol. 2010 Jul;30(1):11-8. (PMID: 21787623)
Wound Repair Regen. 2019 Jan;27(1):114-125. (PMID: 30362646)
J Burn Care Res. 2017 May/Jun;38(3):e605-e613. (PMID: 28328668)
BMC Emerg Med. 2015 Aug 25;15:20. (PMID: 26302780)
J Glob Antimicrob Resist. 2021 Sep;26:140-147. (PMID: 34144200)
Am J Surg. 1998 Aug;176(2A Suppl):26S-38S. (PMID: 9777970)
BMC Complement Altern Med. 2014 May 13;14:157. (PMID: 24886368)
Thromb Res. 2019 Jul;179:56-63. (PMID: 31078121)
Food Chem Toxicol. 1995 Mar;33(3):223-31. (PMID: 7896233)
BMC Complement Altern Med. 2017 Jun 26;17(1):337. (PMID: 28651570)
Mar Drugs. 2010 May 28;8(6):1763-8. (PMID: 20631868)
J Ethnobiol Ethnomed. 2017 Oct 4;13(1):55. (PMID: 28978342)
J Intercult Ethnopharmacol. 2016 Apr 16;5(3):226-32. (PMID: 27366347)
Oxid Med Cell Longev. 2021 Feb 4;2021:8852759. (PMID: 33628388)
Evid Based Complement Alternat Med. 2020 Dec 10;2020:1718708. (PMID: 33376495)
Evid Based Complement Alternat Med. 2021 Oct 19;2021:9369173. (PMID: 34712351)
Adv Wound Care (New Rochelle). 2015 Apr 1;4(4):225-234. (PMID: 25945285)
Evid Based Complement Alternat Med. 2018 Jun 11;2018:2047896. (PMID: 29991951)
Clin Dermatol. 2007 Jan-Feb;25(1):19-25. (PMID: 17276197)
J Exp Pharmacol. 2022 Jul 17;14:221-241. (PMID: 35875331)
J Ethnobiol Ethnomed. 2006 Feb 01;2:8. (PMID: 16451716)
Syst Rev. 2016 Sep 08;5(1):152. (PMID: 27609108)
J Ethnopharmacol. 2006 Jun 15;106(1):44-50. (PMID: 16417980)
J Ethnopharmacol. 2003 Mar;85(1):151-6. (PMID: 12576214)
BMC Complement Altern Med. 2015 Sep 30;15:341. (PMID: 26423525)

0 (Plant Extracts)
0 (Anti-Inflammatory Agents)
0 (Solvents)
9000-07-1 (Carrageenan)

Date Created: 20240710 Date Completed: 20240710 Latest Revision: 20240712

20240712

PMC11236120

10.1371/journal.pone.0306766

38985716